- Home
- EOI vs NRIX Comparison
EOI vs NRIX Comparison
Compare EOI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOI
- NRIX
- Stock Information
- Founded
- EOI 2004
- NRIX 2009
- Country
- EOI United States
- NRIX United States
- Employees
- EOI N/A
- NRIX N/A
- Industry
- EOI Finance/Investors Services
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- EOI Finance
- NRIX Health Care
- Exchange
- EOI Nasdaq
- NRIX Nasdaq
- Market Cap
- EOI 819.4M
- NRIX 766.0M
- IPO Year
- EOI N/A
- NRIX 2020
- Fundamental
- Price
- EOI $21.21
- NRIX $10.58
- Analyst Decision
- EOI
- NRIX Strong Buy
- Analyst Count
- EOI 0
- NRIX 15
- Target Price
- EOI N/A
- NRIX $29.13
- AVG Volume (30 Days)
- EOI 83.6K
- NRIX 676.0K
- Earning Date
- EOI 01-01-0001
- NRIX 10-10-2025
- Dividend Yield
- EOI 7.19%
- NRIX N/A
- EPS Growth
- EOI N/A
- NRIX N/A
- EPS
- EOI N/A
- NRIX N/A
- Revenue
- EOI N/A
- NRIX $88,381,000.00
- Revenue This Year
- EOI N/A
- NRIX $71.51
- Revenue Next Year
- EOI N/A
- NRIX N/A
- P/E Ratio
- EOI N/A
- NRIX N/A
- Revenue Growth
- EOI N/A
- NRIX 41.86
- 52 Week Low
- EOI $14.36
- NRIX $8.18
- 52 Week High
- EOI $18.88
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- EOI 57.86
- NRIX 43.67
- Support Level
- EOI $21.00
- NRIX $9.44
- Resistance Level
- EOI $21.18
- NRIX $10.98
- Average True Range (ATR)
- EOI 0.20
- NRIX 0.54
- MACD
- EOI 0.02
- NRIX -0.04
- Stochastic Oscillator
- EOI 74.36
- NRIX 39.45
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.